ANTIBE THERAPEUTICS INC ORDINARY SHARES (OTCMKTS:ATBPF) Sellers Increased By 757.43% Their Shorts

November 10, 2018 - By Louis Casey

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Logo

The stock of ANTIBE THERAPEUTICS INC ORDINARY SHARES (OTCMKTS:ATBPF) registered an increase of 757.43% in short interest. ATBPF’s total short interest was 86,600 shares in November as published by FINRA. Its up 757.43% from 10,100 shares, reported previously. With 62,100 shares average volume, it will take short sellers 1 days to cover their ATBPF’s short positions.

The stock decreased 4.28% or $0.01 during the last trading session, reaching $0.21. About 220,605 shares traded or 325.15% up from the average. Antibe Therapeutics Inc. (OTCMKTS:ATBPF) has 0.00% since November 10, 2017 and is . It has underperformed by 15.62% the S&P500.

Antibe Therapeutics Inc., together with its subsidiaries, originates, develops, and out-licenses patent protected pharmaceuticals primarily in Canada, Europe, and the United States. The company has market cap of $45.97 million. The company's lead compound is the ATB-346, a hydrogen sulfide-releasing derivative of naproxen that is in Phase II clinical study for the treatment of osteoarthritis, as well as to treat rheumatoid arthritis, ankylosing spondylitis, and general pain reduction. It currently has negative earnings. The Company’s products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of cardiovascular disease and cancer chemoprevention.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>